Molecule Name |
DB12095
|
DrugBank Groups |
Approved
|
Cluster No |
1221
|
Smiles |
ClC4(=CC(N1(N=C(C)C=C1))=C(C(OC2(=NC(=NC(=C2)C3(=CC=C(CC(N)C(=O)O)C=C3))N))C(F)(F)F)C=C4)
|
Download |
mol2, pdbqt
|
TPSA |
142,17
|
Non-H Atoms |
38
|
Non-C/H Atoms |
13
|
Metal-Atoms |
0
|
Electronegative Atoms |
13
|
Stereo Centers |
2
|
Rotatable Bonds |
9
|
Rings Closures |
4
|
Small Rings |
4
|
Aromatic Rings |
4
|
Aromatic Atoms |
23
|
sp3-Atoms |
8
|
Symmetric atoms |
4
|
cLogS |
-6,178
|
MW |
546,936
|
cLogP |
0,9732
|
HBA |
9
|
HBD |
3
|
Ro5 violations |
1
|
Druglikeness |
-16,684
|
DrugScore |
0,208609002468591
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
none
|
Blood-Brain Barrier |
BBB+
|
Human Intestinal Absorption |
HIA+
|
Caco-2 Permeability |
Caco2-
|
P-glycoprotein Substrate |
Non-substrate
|
P-glycoprotein Inhibitor |
Non-inhibitor
|
P-glycoprotein Inhibitor 2 |
Non-inhibitor
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Aqueous solubility |
-4,106
|
Caco-2 Permeability 2 |
0,4216
|
Subcellular localization |
Mitochondria
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 2D6 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 1A2 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 3A4 Inhibitor |
Non-inhibitor
|
CYP Inhibitory Promiscuity |
Low CYP Inhibitory Promiscuity
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition 2 |
Non-inhibitor
|
AMES Toxicity |
Non AMES toxic
|
Carcinogens |
Non-carcinogens
|
Fish Toxicity |
High FHMT
|
Fish Toxicity (pLC50, mg/L) |
1,313
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity (pIGC50, ug/L) |
0,4741
|
Honey Bee Toxicity |
Low HBT
|
Biodegradation |
Not ready biodegradable
|
Acute Oral Toxicity |
III
|
Rat Acute Toxicity (LD50, mol/kg) |
2,3738
|
Carcinogenicity (Three-class) |
Non-required
|